NCT01068782 2026-02-25
Multiple Doses and Regimens of Cabozantinib in Subjects With Grade IV Astrocytic Tumors in First or Second Relapse
Exelixis
Phase 2 Terminated
Exelixis
Grupo Espanol de Tumores Neuroendocrinos
National Cancer Institute (NCI)
University of Alabama at Birmingham
Indiana University
Dana-Farber Cancer Institute
University of Pittsburgh